Ged C, Jean G, Tete M J, Broyer M, Kamoun P
Service de Biochimie, Hôpital Necker Enfants Malades, Paris.
Ann Biol Clin (Paris). 1991;49(9):482-6.
Data on cystine leukocyte content are analyzed in cystinotic patients receiving cysteamine as a depleting agent of cellular cystine. During 2 years, 63 measurements of cystine leucocyte content were performed in 15 cystinotic patients, aged 20 months to 22 years, taking daily 40 to 65 mg/kg of cysteamine. An original method was used to measure leukocyte cystine: a binding protein assay with a specific cystine-binding protein from E. coli. Results were taken individually because of various clinical situations in patients. In 8 patients taking cysteamine regularly, 6 hours after a dose, cystine leukocyte content was between 1 and 2 nmol 1/2 cystine/mg protein, about 10 times less than basal values without treatment and 5 to 10 times more than control subjects. In less compliant patients, cystine leukocyte content was close to basal values without treatment (3 to 25 nmol/mg). Some variability was observed between individuals receiving cysteamine: pharmacokinetic parameters may need further investigation. This sensitive and specific assay helped in controlling compliance and adjusting dosage regimen in each patient. The aim was to maintain a minimum effective dosage in order to avoid toxic side effects of cysteamine.
对接受半胱胺作为细胞内胱氨酸消耗剂的胱氨酸病患者的胱氨酸白细胞含量数据进行了分析。在2年期间,对15名年龄在20个月至22岁之间、每日服用40至65mg/kg半胱胺的胱氨酸病患者进行了63次胱氨酸白细胞含量测量。采用一种原始方法测量白细胞胱氨酸:使用来自大肠杆菌的特异性胱氨酸结合蛋白进行结合蛋白测定。由于患者的各种临床情况,结果是单独获取的。在8名定期服用半胱胺的患者中,给药6小时后,胱氨酸白细胞含量在1至2nmol 1/2胱氨酸/毫克蛋白之间,约为未治疗时基础值的十分之一,比对照受试者高5至10倍。在依从性较差的患者中,胱氨酸白细胞含量接近未治疗时的基础值(3至25nmol/毫克)。在接受半胱胺的个体之间观察到一些变异性:药代动力学参数可能需要进一步研究。这种灵敏且特异的测定有助于控制每位患者的依从性并调整给药方案。目的是维持最低有效剂量,以避免半胱胺的毒副作用。